190 related articles for article (PubMed ID: 32875515)
1. Comparison of Droplet Digital PCR versus qPCR Measurements on the International Scale for the Molecular Monitoring of Chronic Myeloid Leukemia Patients.
Cortés AA; Olmedillas S; Serrano-López J; Lainez-González D; Castaño T; Iñiguez R; Lopez-Lorenzo JL; García A; Atance M; Sánchez RNS; Lopez CB; Arranz MG; Sillero PL; Alonso-Dominguez JM
Mol Diagn Ther; 2020 Oct; 24(5):593-600. PubMed ID: 32875515
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.
Franke GN; Maier J; Wildenberger K; Cross M; Giles FJ; Müller MC; Hochhaus A; Niederwieser D; Lange T
J Mol Diagn; 2020 Jan; 22(1):81-89. PubMed ID: 31669230
[TBL] [Abstract][Full Text] [Related]
3. One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia.
Martinez RJ; Kang Q; Nennig D; Bailey NG; Brown NA; Betz BL; Tewari M; Thyagarajan B; Bachanova V; Mroz P
Arch Pathol Lab Med; 2022 Jan; 146(1):92-100. PubMed ID: 33769465
[TBL] [Abstract][Full Text] [Related]
4. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
Wang WJ; Zheng CF; Liu Z; Tan YH; Chen XH; Zhao BL; Li GX; Xu ZF; Ren FG; Zhang YF; Chang JM; Wang HW
Eur J Haematol; 2018 Sep; 101(3):291-296. PubMed ID: 29691899
[TBL] [Abstract][Full Text] [Related]
5. Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.
Kjaer L; Skov V; Andersen MT; Aggerholm A; Clair P; Gniot M; Soeby K; Udby L; Dorff MH; Hasselbalch H; Pallisgaard N
Eur J Haematol; 2019 Jul; 103(1):26-34. PubMed ID: 30985947
[TBL] [Abstract][Full Text] [Related]
6. Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.
Brown JT; Beldorth IJ; Laosinchai-Wolf W; Fahey ME; Jefferson KL; Ruskin AK; Roth JJ; Cai L; Watt CD; Press RD; Yang F; Hedges JB; Andruss BF
J Mol Diagn; 2019 Jul; 21(4):718-733. PubMed ID: 31026597
[TBL] [Abstract][Full Text] [Related]
7. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
[TBL] [Abstract][Full Text] [Related]
8. Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR.
Jennings LJ; George D; Czech J; Yu M; Joseph L
J Mol Diagn; 2014 Mar; 16(2):174-9. PubMed ID: 24389534
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of tyrosine kinase inhibitors based on
Kim Y; Kim S; Lee JM; Ahn A; Yoo JW; Lee JW; Cho B; Chung NG; Kim Y; Kim M
Front Pediatr; 2022; 10():928136. PubMed ID: 35967571
[TBL] [Abstract][Full Text] [Related]
10. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale.
Furuya D; Moriai M; Koizumi Y; Endo T; Asanuma K; Yanagihara N; Takahashi S
Int J Clin Oncol; 2019 Jul; 24(7):871-875. PubMed ID: 30798394
[TBL] [Abstract][Full Text] [Related]
11. Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay.
Chung HJ; Hur M; Yoon S; Hwang K; Lim HS; Kim H; Moon HW; Yun YM
Ann Lab Med; 2020 Jan; 40(1):72-75. PubMed ID: 31432643
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL1 p210 screening for chronic myeloid leukemia in patients with peripheral blood cytoses.
Fenu E; O'Neill SS; Insuasti-Beltran G
Int J Lab Hematol; 2021 Dec; 43(6):1458-1464. PubMed ID: 34185393
[TBL] [Abstract][Full Text] [Related]
13. Programme for Harmonization to the International Scale in Latin America for BCR-ABL1 quantification in CML patients: findings and recommendations.
Ruiz MS; Sánchez MB; Vera Contreras YM; Agrielo E; Alonso M; Altuna ME; Anchordoqui MS; Asinari M; Bonetto ME; Camargo M; Giere I; González J; Granda Alacote AC; Guerra J; Gutiérrez M; Maldonado C; Makiya R; Manrique G; Monaco ME; Rozo JC; Santamaría C; Seravalle A; Zea O; Zubillaga MN; Mordoh J; Larripa I; Bianchini M
Clin Chem Lab Med; 2020 Nov; 58(12):2025-2035. PubMed ID: 32374276
[TBL] [Abstract][Full Text] [Related]
14. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
Salmon M; White HE; Zizkova H; Gottschalk A; Motlova E; Cerveira N; Colomer D; Coriu D; Franke GN; Gottardi E; Izzo B; Jurcek T; Lion T; Schäfer V; Venturi C; Vigneri P; Zawada M; Zuna J; Hovorkova L; Koblihova J; Klamova H; Markova MS; Srbova D; Benesova A; Polivkova V; Zackova D; Mayer J; Roeder I; Glauche I; Ernst T; Hochhaus A; Polakova KM; Cross NCP
Leukemia; 2022 Jul; 36(7):1879-1886. PubMed ID: 35676453
[TBL] [Abstract][Full Text] [Related]
15. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.
Arora R; Press RD
Leuk Lymphoma; 2017 Jan; 58(1):8-16. PubMed ID: 27412040
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.
Press RD; Kamel-Reid S; Ang D
J Mol Diagn; 2013 Sep; 15(5):565-76. PubMed ID: 23810242
[TBL] [Abstract][Full Text] [Related]
17. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a novel multiplex RT-qPCR assay for the quantification of leukemia-associated BCR-ABL1 translocation.
Kottwitz D; El Hadi H; El Amrani M; Cabezas S; Dehbi H; Nadifi S; Quessar A; Colomer D; Moumen A; Sefrioui EL
Int J Hematol; 2015 Sep; 102(3):335-41. PubMed ID: 26243622
[TBL] [Abstract][Full Text] [Related]
19. Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia.
Shelton DN; Bhagavatula P; Sepulveda N; Beppu L; Gandhi S; Qin D; Hauenstein S; Radich J
PLoS One; 2022; 17(3):e0265278. PubMed ID: 35298544
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.
Spiess B; Rinaldetti S; Naumann N; Galuschek N; Kossak-Roth U; Wuchter P; Tarnopolscaia I; Rose D; Voskanyan A; Fabarius A; Hofmann WK; Saußele S; Seifarth W
PLoS One; 2019; 14(3):e0214305. PubMed ID: 30897165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
